What Is the Intact PTH Test and What Do Results Mean?

The intact PTH test is a blood test that measures parathyroid hormone, a key regulator of calcium and phosphorus levels in your body. Doctors order it most often when blood calcium is abnormally high or low, when kidney disease is being managed, or when bone disorders need investigation. The word “intact” refers to the assay’s design: it attempts to measure the full-length hormone molecule rather than just fragments of it, though that distinction turns out to be less clean-cut than the name implies.

What Parathyroid Hormone Does

Your four parathyroid glands, each about the size of a grain of rice, sit behind the thyroid in your neck. When blood calcium dips even slightly, these glands release PTH, which acts on bone, kidneys, and indirectly on the gut to restore calcium to normal. In the kidneys, PTH promotes calcium reabsorption and boosts the active form of vitamin D while reducing phosphate reabsorption.¹ That active vitamin D in turn helps your intestines absorb more calcium from food. The net effect is a tightly controlled feedback loop: calcium rises, PTH secretion falls; calcium drops, PTH secretion rises. Disruptions in this loop are exactly what the intact PTH test is designed to detect.

How the Assay Works

PTH is a chain of 84 amino acids, and your blood always contains both the full chain and various broken-off fragments, particularly large C-terminal pieces. Early PTH assays measured many of those fragments indiscriminately, which made results unreliable, especially in people with kidney disease whose bodies clear fragments slowly. The intact PTH assay, also called a second-generation assay, was developed to solve that problem. It uses a “sandwich” approach: one antibody grabs the C-terminal end of the molecule, and a second antibody grabs the N-terminal end, so in theory only the whole 1-84 chain gets detected.²

In practice, there is a catch. The N-terminal antibody in second-generation assays does not target the very first few amino acids of the chain. That means a large fragment called PTH 7-84, which is missing only those first six amino acids, slips through and gets counted alongside the full hormone.² For most people with healthy kidneys, these fragments are present in small quantities and the test works well enough. For people on dialysis, where fragment buildup can be substantial, the numbers can be misleadingly high.

Third-Generation Assays and Why the Distinction Matters

Third-generation, or “bio-intact,” assays were designed to fix the fragment problem. They use a detection antibody aimed at those first four amino acids that the second-generation assay misses, which blocks PTH 7-84 from registering.³ Testing has confirmed that this third-generation design is unaffected even by a massive excess of 7-84 fragments, while the second-generation assay reacts to those fragments just as strongly as it does to the real hormone.⁴

The practical consequence is that third-generation results come in substantially lower than second-generation results drawn from the same blood sample. In dialysis patients, third-generation values run more than 40 percent lower; in pre-dialysis kidney disease patients, roughly 30 percent lower.⁵ This is not a trivial academic difference. If your doctor is tracking your PTH over time, a switch in assay generation mid-course can make it look like your levels suddenly plummeted even though nothing changed physiologically. When reviewing PTH results, especially in kidney disease, knowing which assay was used is important context that often goes unmentioned on the lab report.

What Normal Results Look Like

Most laboratories report a reference range for the intact PTH assay somewhere around 10 to 65 pg/mL, though exact cutoffs vary by lab and assay manufacturer. A result within that range, alongside normal calcium and vitamin D levels, usually means the parathyroid glands are functioning appropriately. The result only makes sense in the context of other labs drawn at the same time, particularly serum calcium, phosphorus, vitamin D, and creatinine. A PTH level that looks “normal” can actually be abnormal if your calcium is simultaneously elevated, because healthy parathyroid glands should have suppressed PTH secretion in response to the high calcium.

High PTH Results

Elevated PTH generally falls into one of two categories: the glands are overactive on their own (primary hyperparathyroidism), or they are responding appropriately to some other problem that keeps calcium low or phosphorus high (secondary hyperparathyroidism).

Primary hyperparathyroidism is the most common cause of high calcium combined with high or inappropriately normal PTH. It is usually driven by a single benign tumor (adenoma) on one of the parathyroid glands. Most people with this condition are discovered incidentally through routine blood work and may have few or no symptoms. Treatment, when warranted, is surgical removal of the overactive gland.

Secondary hyperparathyroidism is most often seen in chronic kidney disease. As kidney function declines, the kidneys lose the ability to excrete phosphorus and to produce active vitamin D. Calcium levels fall, phosphorus levels rise, and the parathyroid glands ramp up PTH production in a sustained effort to compensate.⁶ PTH levels in advanced kidney disease can climb to many times the upper limit of the normal range.

Other causes of high PTH include severe vitamin D deficiency (which deprives the body of the calcium absorption it needs, triggering compensatory PTH rises), high phosphorus intake, and certain medications.

PTH Targets in Kidney Disease

Interpreting PTH in someone with chronic kidney disease is a different exercise entirely from interpreting it in the general population. The standard reference range does not apply. In patients on dialysis, international guidelines have recommended different target windows depending on the era and the guideline body. Older guidelines from the National Kidney Foundation suggested a target of 150 to 300 pg/mL for dialysis patients. The more recent KDIGO guidelines relaxed that target to two to nine times the upper limit of normal, which works out to roughly 130 to 600 pg/mL.⁷

The wider KDIGO range was adopted in part because the older, tighter range proved difficult to achieve. In one study, only about 36 percent of dialysis patients fell within the older target, while about 63 percent met the newer, broader KDIGO window.⁷ The shift also reflects growing recognition that the relationship between PTH levels and bone disease in kidney patients is not as linear as once assumed. Very high PTH is clearly harmful, and very low PTH in dialysis patients signals a different but equally serious bone problem (adynamic bone disease, where bone turnover is too sluggish). In between lies a gray zone where the “right” PTH level for a given patient depends on the trend over time more than any single number.

Low PTH Results

A low PTH level means the parathyroid glands are either damaged, suppressed, or not receiving the signals they need to secrete the hormone. The most common cause in clinical practice is surgical removal or accidental injury to the parathyroid glands during thyroid surgery. In one large study of over a thousand total thyroidectomy patients, about 18 percent had a PTH below 10 pg/mL after surgery, and those patients were more likely to have had additional neck procedures or parathyroid tissue inadvertently removed.⁸ Most post-surgical hypoparathyroidism resolves within weeks to months, but a minority of cases become permanent.

Low PTH can also signal that something is actively suppressing the glands. Hypercalcemia from a non-parathyroid source, such as cancer, is a classic example. In malignancy-related hypercalcemia, tumors often produce a protein that mimics PTH’s effects on bone and kidneys, driving calcium up while the actual parathyroid glands shut down in response.⁹ The pattern of high calcium with suppressed PTH is an important diagnostic clue that the problem is not in the parathyroid glands themselves.

Sample Handling and Why It Affects Your Results

PTH is a fragile molecule that degrades quickly once blood is drawn. How the sample is collected, processed, and stored genuinely matters to the accuracy of your result. A systematic review found that PTH remains stable in EDTA-preserved whole blood at room temperature for at least 24 hours but degrades in clotted blood (the standard serum tube) after roughly three hours at room temperature. Separated EDTA plasma stays reliable for at least 48 hours at room temperature and at least 72 hours refrigerated, while separated serum lasts about 24 hours refrigerated.¹⁰

Speed of processing matters too. Delaying separation of the sample by even two hours after collection led to a roughly 7 percent drop in measured PTH in EDTA plasma and about a 4 percent drop in serum from plain tubes.¹¹ At longer storage times the losses become dramatic: serum left at room temperature for eight days showed PTH values that had collapsed to a fraction of the original measurement.¹¹ Labs that are far from the draw site, or that batch-process samples at the end of the day, risk returning falsely low results. If your PTH comes back unexpectedly low on a test sent to a reference lab, it is worth asking how the sample was handled.

Frozen storage introduces its own quirks. After one day frozen, EDTA and serum samples perform similarly, but by five days frozen, EDTA samples degrade faster than serum.¹² The optimal tube type and workflow depend on the lab’s turnaround time, which is why different institutions have different collection protocols.

Things That Can Throw Off Your Results

Beyond sample handling, several biological and chemical factors can make PTH results misleading.

Biotin supplements are a well-documented troublemaker. Biotin (vitamin B7) is found in hair, skin, and nail supplements, often at doses far above the dietary requirement. Unbound biotin molecules in the blood interfere with the type of immunoassay used to measure PTH, artificially depressing the result.¹³ The degree of interference varies by platform. In one study using a Roche assay, neutralizing the biotin caused measured PTH to jump from a median of about 8 pg/mL to about 28 pg/mL, a more than threefold increase.¹⁴ A Beckman assay tested alongside showed no significant interference. If you take biotin supplements and get a puzzlingly low PTH result, mention the supplement to your doctor. Most labs recommend stopping biotin at least 48 to 72 hours before the blood draw.

Magnesium deficiency is another underappreciated confounder. Severe hypomagnesemia impairs the parathyroid glands’ ability to secrete PTH, creating what is sometimes called paradoxical hypoparathyroidism: calcium is low, which should trigger PTH release, but the glands cannot respond without adequate magnesium. The resulting hypocalcemia cannot be corrected by calcium or vitamin D supplementation alone until the magnesium deficit is addressed.¹⁵ Checking magnesium alongside PTH and calcium is essential when the numbers do not add up.

Timing and Natural Variation

PTH is not a static hormone. It follows a circadian rhythm, with levels peaking during the night and reaching their lowest point in mid-morning.¹⁰ This means that drawing blood at 8 a.m. versus 4 p.m. can give noticeably different readings even when nothing else has changed. In the northern hemisphere, PTH concentrations also tend to be higher in winter than summer, a pattern that tracks with seasonal swings in vitamin D production from sunlight exposure.¹⁰ For serial monitoring, drawing at a consistent time of day helps reduce noise.

Blood-draw location matters as well. Central venous PTH concentrations run higher than peripheral venous concentrations.¹⁰ This is mostly relevant in hospitalized patients who may have blood drawn from a central line one day and from an arm vein the next.

How Medications Shift PTH Levels

Several common blood pressure medications have measurable effects on PTH. In a large community-based study of people with normal kidney function, thiazide diuretics were associated with PTH levels about 3 pg/mL lower than in non-users. Loop diuretics, by contrast, were linked to PTH levels roughly 15 pg/mL higher. Among calcium-channel blockers, the dihydropyridine subtype (which includes amlodipine and nifedipine) was associated with PTH about 5 pg/mL higher, while non-dihydropyridine calcium-channel blockers showed no meaningful effect.¹⁶

The mechanism tracks with what each drug does to calcium handling. Thiazides reduce calcium loss through the kidneys, which nudges blood calcium up and gives the parathyroid glands less reason to secrete PTH. Loop diuretics do the opposite: they increase calcium excretion, which over time can push PTH production higher. These shifts are typically modest and do not cause disease on their own, but they are worth knowing about if your PTH is borderline and you are on one of these drugs.

Intraoperative PTH Monitoring

One of the more dramatic uses of the intact PTH test takes place during parathyroid surgery itself. Because PTH has a very short half-life in the blood (about three to five minutes), surgeons can draw blood before removing a suspected overactive gland and again ten to fifteen minutes after excision. If PTH drops by more than 50 percent from the pre-excision peak (the “Miami criterion”), the surgeon can be confident that all the overactive tissue has been removed and can close without exploring further.¹⁷ Both the Miami criterion and a related “dual criterion” that also requires the level to fall into the normal range have been shown to reliably predict that calcium will normalize after surgery.¹⁸

If the drop is insufficient, the surgeon knows to keep looking for additional abnormal tissue, potentially extending the exploration to the other side of the neck.¹⁹ This real-time feedback has transformed parathyroid surgery, allowing many operations to be performed through smaller incisions with shorter operating times because the surgeon does not need to visually inspect all four glands when the lab data confirms the problem has been resolved.

PTH During Pregnancy

Pregnancy changes PTH physiology in ways that can confuse interpretation. Calcium demands increase substantially as the fetus builds its skeleton, and the body adapts partly by increasing intestinal calcium absorption through higher levels of active vitamin D produced by the placenta. In one study comparing high-risk pregnant women with non-pregnant controls, the median PTH in pregnant women was about 32 pg/mL versus about 46 pg/mL in non-pregnant women, a statistically significant difference.²⁰ The range was extremely wide in the pregnant group, from less than 1 pg/mL to over 500 pg/mL, reflecting diverse pathologies. A lower PTH during pregnancy does not necessarily mean something is wrong; the body’s alternative calcium-absorption pathways may simply be handling more of the load.

When High Calcium and High PTH Do Not Mean What You Think

A pattern of mildly elevated calcium with an inappropriately normal or slightly elevated PTH is the textbook setup for primary hyperparathyroidism. But an uncommon inherited condition called familial hypocalciuric hypercalcemia (FHH) produces almost the same lab picture. In FHH, a genetic variant makes calcium-sensing receptors throughout the body less sensitive, so the parathyroid glands “think” calcium is lower than it actually is and keep secreting PTH. The body’s kidneys are similarly fooled and hold onto calcium instead of excreting it.²¹

The distinction matters because FHH is benign and does not require surgery, while primary hyperparathyroidism often does. The classic differentiator is a 24-hour urine calcium collection: people with primary hyperparathyroidism tend to excrete more calcium, while those with FHH excrete very little. But the overlap between the two conditions can be considerable, and individual cases sometimes straddle the diagnostic cutoffs, making the workup genuinely tricky.²² Genetic testing for mutations in the calcium-sensing receptor gene has become a more definitive tool when the urine calcium results are ambiguous. If you have been told you have mildly elevated calcium and PTH, and especially if a family member has the same pattern, FHH is worth discussing with your doctor before anyone schedules surgery.

1
Molecular Metabolism. Parathyroid hormone (PTH) regulation of metabolic homeostasis: An old dog teaches us new tricks
2
Endocrine Reviews. Clinical Guidelines and PTH Measurement: Does Assay Generation Matter?
3
PubMed Central. Comparison of second and third-generation parathyroid hormone assays at a tertiary hospital in South Africa
4
PubMed. Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone
5
PMC Central. Comparison of Second- and Third-Generation Parathyroid Hormone Test Results in Patients with Chronic Kidney Disease
6
ScienceDirect. Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy
7
PubMed Central. KDIGO guidelines: how difficult is reaching the ‘target’?
8
PubMed Central. Hypoparathyroidism after Total Thyroidectomy: Incidence and Resolution
9
Wiley Online Library (CA Cancer J Clin). Hypercalcemia and cancer: Differential diagnosis and treatment
10
PubMed. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review
11
PubMed Central. Stability and validity of intact parathyroid hormone levels in different sample types and storage conditions
12
PubMed. Stability of intact parathyroid hormone in samples from hemodialysis patients
13
PubMed. Falsely low parathyroid hormone secondary to biotin interference: a case series
14
Clinical Biochemistry. Serum biotin interference: A troublemaker in hormone immunoassays
15
PMC. Paradoxical Inadequate Parathyroid Hormone Secretion Secondary to Severe Hypomagnesemia: A Review of the Literature
16
PubMed Central. Parathyroid Hormone and the Use of Diuretics and Calcium-Channel Blockers: The Multi-Ethnic Study of Atherosclerosis
17
Endocrinology and Metabolism. Intraoperative Parathyroid Hormone Monitoring in the Surgical Management of Sporadic Primary Hyperparathyroidism
18
PubMed Central. Chasing the Drop: Miami Versus Dual Criteria for Intraoperative Parathyroid Hormone Monitoring in Primary Hyperparathyroidism
19
Current Problems in Surgery. Intraoperative parathyroid hormone monitoring criteria in secondary and tertiary hyperparathyroidism: A systematic review
20
PubMed Central. Cross-sectional study of serum parathyroid hormone level in high-risk pregnancies as compared to nonpregnant control
21
PubMed. Differentiating familial hypocalciuric hypercalcemia from primary hyperparathyroidism
22
PubMed Central. Primary hyperparathyroidism versus familial hypocalciuric hypercalcemia: a challenging diagnostic evaluation in an adolescent female